Oct 16, 2026 04:05PM
Oct 5, 2026 08:00AM
Sep 28, 2026 08:00AM
Sep 28, 2026 08:00AM
Sep 11, 2026 04:05PM
Jun 29, 2026 08:00AM
May 27, 2026 08:00AM 4DMT to Participate in Upcoming Investor Conferences
May 15, 2026 04:05PM
Jan 17, 2026 08:00AM
Nov 20, 2025 08:00PM
Nov 20, 2025 08:00PM
Oct 31, 2025 09:20AM
Oct 30, 2025 11:02PM
Oct 30, 2025 11:02PM 4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific
Oct 14, 2025 08:00AM
May 5, 2025 08:00AM
May 1, 2025 08:01AM
May 1, 2025 08:00AM
Mar 27, 2025 08:00AM
Feb 19, 2025 08:00AM
Feb 8, 2025 02:30PM 4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program
Jan 29, 2025 08:00AM
Jan 10, 2025 08:07AM
Jan 10, 2025 08:00AM
Sep 19, 2024 08:06AM
Jun 8, 2024 04:30PM
Mar 28, 2024 01:32PM
Feb 7, 2024 05:33AM 4D Molecular Therapeutics (FDMT) Prices Upsized 6.6M Share Offering at $29.50/sh
Feb 7, 2024 05:21AM
Feb 6, 2024 11:27PM
Feb 5, 2024 04:05PM
Feb 5, 2024 04:05PM
Feb 5, 2024 05:44AM
Feb 3, 2024 05:00PM
Jan 29, 2024 08:00AM 4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden
Jan 23, 2024 08:07AM
Nov 9, 2023 04:19PM
Oct 30, 2023 08:01AM
Oct 30, 2023 08:00AM
Jul 31, 2023 05:41AM
Jul 29, 2023 12:00PM
Jul 10, 2023 07:30PM Astellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT's Proprietary Intravitreal R100 Vector for Rare Ophthalmic Targets
Jul 5, 2023 05:35AM
Jun 7, 2023 04:10PM
Jun 7, 2023 04:10PM
Jun 1, 2023 08:00AM
May 11, 2023 08:00AM
May 11, 2023 08:00AM
May 9, 2023 04:05PM 4D Molecular Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 8, 2023 04:05PM

334,274 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All